| Target Professions: | DO, MD, Nurse Practitioner, Physician Associate/Assistant |
| Target Specialties: | Oncology |
| Credits Available: | 4.75 AMA PRA Category 1 Credit™/ MOC Points |
This curriculum examines the latest advancements in antibody-drug conjugate (ADC) therapy for metastatic triple-negative breast cancer (mTNBC) and HER2-low (HER+/HER2-) breast cancer. It provides insights into mechanisms of action, emerging clinical data, and strategies for integrating ADCs into treatment regimens to improve patient outcomes. Expert-led discussions and case-based learning will support clinicians in individualizing therapy and addressing real-world challenges in ADC use.
Answer the following questions to assess your knowledge on the use of ADCs in metastatic breast cancer and managing toxicities.
This module provides a comprehensive overview of metastatic triple-negative breast cancer (mTNBC), highlighting its aggressive nature and poor prognosis.
This module explores the role of antibody-drug conjugates (ADCs), a rapidly evolving class of targeted therapies that deliver cytotoxic agents directly to cancer cells.
This module offers an overview of the evolving treatment landscape for HR+/HER2- breast cancer.
This module will examine the mechanisms, clinical benefits, and safety of ADCs, along with emerging data that highlight their potential in addressing resistance to endocrine and chemotherapy.
This module examines key adverse events associated with antibody-drug conjugates, including neutropenia, anemia, thrombocytopenia, and gastrointestinal (GI) toxicity.
This module continues an exploration of critical strategies for monitoring and managing adverse events associated with antibody-drug conjugates (ADCs).
Now that you have reviewed the self-study modules, answer the following questions to assess your knowledge on the use of ADCs in metastatic breast cancer and managing toxicities.
This discussion will revisit key material from the self-assessments. Participants will explore the latest data on ADCs, their mechanisms of action, and clinical applications, ensuring a solid foundation for integrating these therapies into practice.
This activity features a 67-year-old woman with mTNBC being considered for sacituzumab govitecan. The case covers treatment setting considerations and management of treatment-related adverse events.
This activity features a 58-year-old woman with metastatic HR+/HER2- breast cancer who is being treated with trastuzumab deruxtecan. This patient case activity discusses treatment considerations and management of treatment-related adverse events.
Please detail how you will integrate new insights into the diagnosis, treatment, and management of mTNBC and HER2-/HER+ breast cancer. It should also address potential barriers and outline clear goals you have that will enhance your clinical practice.
This discussion will explore case-based challenges in managing mTNBC and HER2-/HER+ breast cancer, focusing on real-world strategies, emerging therapies, and personalized patient care. Participants will share insights and collaborate on overcoming treatment barriers.
